中国P站

Reactive oxygen species; Oxidative stress; Liver toxicity; Kidney injury; Antioxidant defense; Lipid peroxidation; Nephrotoxicity; Hepatotoxicity; Glutathione; Superoxide dismutase; Catalase; Mitochondrial dysfunction; Experimental models; Drug-induced toxicity; Free radicals

Introduction

Hepatorenal toxicity refers to simultaneous functional or structural damage to the liver and kidneys, often as a consequence of drug exposure, xenobiotic accumulation, or systemic oxidative stress. The liver and kidneys, as central organs in detoxification and excretion, are particularly vulnerable to damage by reactive oxygen species (ROS). ROS are chemically reactive molecules derived from oxygen, including superoxide anion (O鈧�•鈦�), hydrogen peroxide (H鈧侽鈧�), and hydroxyl radicals (•OH). While physiologically produced at low levels during normal metabolism, excessive ROS generation leads to oxidative stress, contributing significantly to cellular injury in hepatorenal systems. Experimental models have consistently demonstrated the critical role of ROS in the pathogenesis of hepatorenal toxicity, helping unravel underlying mechanisms and potential therapeutic targets. This article explores the biochemical and molecular role of ROS in experimental hepatorenal toxicity, emphasizing its contribution to oxidative damage, inflammation, and apoptotic cell death [1].

Description

In normal physiological conditions, ROS are generated as byproducts of mitochondrial respiration and enzymatic reactions involving cytochrome P450 oxidases, xanthine oxidase, and NADPH oxidases. Cells counterbalance ROS production with antioxidant defense systems including superoxide dismutase (SOD), catalase, glutathione (GSH), and glutathione peroxidase (GPx). When the balance shifts toward excessive ROS generation or diminished antioxidant capacity, oxidative stress ensues, leading to structural and functional damage in hepatic and renal tissues [2]. Experimental models of hepatorenal toxicity often employ xenobiotics such as acetaminophen (APAP), cisplatin, carbon tetrachloride (CCl鈧�), gentamicin, and doxorubicin to study the impact of oxidative stress. These agents provoke the overproduction of ROS either by disrupting mitochondrial electron transport, redox cycling, or through bioactivation by cytochrome P450 enzymes. ROS then target lipids, proteins, and DNA, compromising cell membrane integrity, mitochondrial function, and genomic stability [3]. One of the most studied models is acetaminophen-induced hepatorenal toxicity. At overdose levels, APAP is metabolized by CYP2E1 into the reactive intermediate N-acetyl-p-benzoquinone imine (NAPQI), which depletes glutathione and binds to cellular proteins, leading to mitochondrial ROS production. Similarly, in cisplatin-induced nephrotoxicity, cisplatin accumulates in proximal tubule cells, leading to mitochondrial damage, increased ROS formation, and subsequent activation of cell death pathways [4]. Lipid peroxidation is a prominent feature of ROS-mediated toxicity. ROS attack polyunsaturated fatty acids in membrane phospholipids, generating reactive aldehydes such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), which further propagate oxidative damage and protein adduct formation. Protein oxidation impairs enzymatic functions and signaling cascades, while oxidative DNA damage results in strand breaks and base modifications, contributing to mutagenesis and cell death [5].

Discussion

Experimental evidence strongly supports the role of ROS as a major pathogenic factor in hepatorenal toxicity. In APAP-induced models, ROS are generated in the mitochondria shortly after GSH depletion. The overproduction of superoxide and peroxynitrite leads to mitochondrial membrane permeabilization, ATP depletion, and the release of pro-apoptotic factors like cytochrome c and apoptosis-inducing factor (AIF). Mitochondrial dysfunction also exacerbates ROS generation, creating a feedback loop that intensifies cellular injury [6].

Similarly, in nephrotoxicity induced by aminoglycosides like gentamicin, ROS production is central to the pathophysiology. Gentamicin accumulates in the renal cortex and stimulates NADPH oxidase and iron-catalyzed Fenton reactions, leading to hydroxyl radical formation. The resulting oxidative stress disrupts mitochondrial respiration, damages lysosomal membranes, and induces tubular necrosis. Pretreatment with antioxidants such as N-acetylcysteine (NAC), vitamin E, or melatonin significantly attenuates renal damage, reinforcing the role of ROS in mediating nephrotoxicity [7]. CCl鈧�-induced liver injury is another classical model where ROS generation is central. Metabolism of CCl鈧� by CYP2E1 results in the formation of the trichloromethyl radical (•CCl鈧�), which reacts with oxygen to form peroxy radicals. These initiate lipid peroxidation and membrane disruption in hepatocytes. The oxidative stress also activates Kupffer cells, the liver-resident macrophages, which produce additional ROS and pro-inflammatory cytokines like TNF-α, amplifying tissue damage. An important link between ROS and inflammation is the activation of redox-sensitive transcription factors such as NF-κB and AP-1. These transcription factors upregulate the expression of pro-inflammatory cytokines and adhesion molecules, contributing to inflammatory cell infiltration in hepatic and renal tissues. In models of LPS-induced endotoxemia, for instance, ROS act as secondary messengers to amplify inflammatory responses in both liver and kidneys [8].

Antioxidant defense mechanisms are critically impaired in hepatorenal toxicity. GSH, a tripeptide that detoxifies ROS, is often depleted early in oxidative injury. Enzymes such as SOD and catalase are either overwhelmed or downregulated, further tipping the redox balance toward oxidative damage. Experimental studies show that boosting antioxidant defenses, either through gene therapy or pharmacological agents, can significantly protect against hepatorenal injury. Experimental interventions targeting ROS production also provide mechanistic insights. For instance, inhibition of CYP2E1 in APAP toxicity reduces NAPQI formation and subsequent ROS production. Mitochondrial-targeted antioxidants like MitoQ and SS-31 have shown promise in experimental models by localizing to mitochondria and neutralizing ROS at their primary site of generation. In cisplatin-induced models, the use of iron chelators like deferoxamine prevents hydroxyl radical formation, demonstrating the role of iron in ROS-mediated renal injury [9]. Furthermore, the role of nitric oxide (NO) and its interaction with ROS cannot be overlooked. Under oxidative conditions, NO reacts with superoxide to form peroxynitrite (ONOO鈦�), a potent oxidant that nitrates tyrosine residues on proteins, disrupts mitochondrial enzymes, and causes DNA strand breaks. Inhibition of inducible nitric oxide synthase (iNOS) has been shown to reduce hepatorenal damage in endotoxin and drug-induced models, highlighting the complex interplay between NO and ROS [10].

Conclusion

Reactive oxygen species play a central and multifaceted role in the pathogenesis of hepatorenal toxicity in experimental models. They act as both initiators and amplifiers of cellular injury by promoting lipid peroxidation, protein oxidation, mitochondrial dysfunction, and apoptosis. Experimental studies using xenobiotics such as APAP, CCl鈧�, gentamicin, and cisplatin have provided critical insights into the biochemical mechanisms by which ROS mediate organ damage. Disruption of antioxidant defenses, activation of redox-sensitive signaling pathways, and induction of inflammatory responses are hallmark features of ROS-driven hepatorenal injury. Targeting ROS production and enhancing antioxidant capacity remain key strategies for therapeutic intervention. As research continues to elucidate the molecular intricacies of ROS in hepatorenal systems, novel antioxidant therapies and protective agents hold promise for mitigating the adverse effects of oxidative stress in clinical settings.

References

1. Iwata H, Kojima R, Okuno Y (2021) Springer.

   ,

2. Altman RB (2017) Clin Pharmacol Ther 101: 585-586.

   , ,

3. Kompa B, Hakim JB, Palepu A, Kompa KG, Smith M (2022) Drug Saf 45: 477-491.

   , ,

4. Lapkin S, Levett-Jones T, Chenoweth L, Johnson M (2016) J Nurs Manag 24: 845-858.

   , ,

5. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, et al. (2001) N Engl J Med 345: 325-334.

   , ,

6. Morales JO, Vuddanda PR, Velaga S (2021) Fundam Drug Deliv pp 433-448.

   , ,

7. Vergara XC, Sevilla A, D'Souza SL, Ang YS, Schaniel C, et al. (2010) Nature 465: 808-812.

   , ,

8. Casimiro MC, Knollmann BC, Ebert SN, Vary JC, Greene AE, et al. (2001) Proc Natl Acad Sci USA 98: 2526-2531.

   , ,

9. Caspi O, Huber I, Gepstein A, Arbel G, Maizels L, et al. (2013) Circ Cardiovasc Genet 6: 557-568.

   , ,

10. Dubois NC, Craft AM, Sharma P, Elliott DA, Stanley EG, et al. (2011) Nat Biotechnol 29: 1011-1018.

    , ,